A First-in-human Phase 1 Dose Escalation Study of SAR428926 in Patients With Advanced Solid Tumors

Trial Profile

A First-in-human Phase 1 Dose Escalation Study of SAR428926 in Patients With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs SAR 428926 (Primary)
  • Indications Breast cancer; Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 06 Dec 2017 Status changed from recruiting to active, no longer recruiting.
    • 11 Oct 2017 Planned End Date changed from 30 Dec 2019 to 20 Apr 2020.
    • 11 Oct 2017 Planned primary completion date changed from 30 Dec 2019 to 20 Apr 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top